Abstract
The effects of mutations in continuously emerging variants of SARS-CoV-2 are a major concern for the performance of rapid antigen tests. To evaluate the impact of mutations on 17 antibodies used in 11 commercially available antigen tests with emergency use authorization, we measured antibody binding for all possible Nucleocapsid point mutations using a mammalian surface-display platform and deep mutational scanning. The results provide a complete map of the antibodies’ epitopes and their susceptibility to mutational escape. Our data predict no vulnerabilities for detection of mutations found in variants of concern. We confirm this using the commercial tests and sequence-confirmed COVID-19 patient samples. The antibody escape mutational profiles generated here serve as a valuable resource for predicting the performance of rapid antigen tests against past, current, as well as any possible future variants of SARS-CoV-2, establishing the direct clinical and public health utility of our system.
Keywords: SARS-CoV-2 Nucleocapsid protein; antibodies; deep mutational scanning; epitope mapping; mammalian surface-display; rapid diagnostic tests; variants.
【저자키워드】 antibodies, Rapid diagnostic tests, SARS-CoV-2 nucleocapsid protein, epitope mapping, deep mutational scanning, variants., mammalian surface-display, 【초록키워드】 public health, SARS-CoV-2, Mutation, antibody, susceptibility, diagnostic, variants of concern, Emergency use authorization, variants, Antigen, Antibody binding, Rapid antigen tests, rapid antigen test, utility, epitope, predict, platform, Point mutation, COVID-19 patient, profile, valuable resource, mammalian, variants of SARS-CoV-2, Effect, Complete, evaluate, the antibody, 【제목키워드】 SARS-CoV-2, rapid antigen test, escape mutation, deep, identify,